注射用盐酸曲拉西利降低骨髓抑制预算影响分析OA

OBJECTIVE:To predict the 5-year budget impact of Trilaciclib for injection on the National Basic Medical Insurance Fund after its inclusion in the National Reimbursement Drug List at the end of 2024 from the perspective of health insurance payers.METHODS:The target population of this study was patients with extensive-stage small-cell lung cancer(ES-SCLC)receiving no systematic chemotherapy.Trilaciclib was administered prior to a platinum/etoposide-combination regimen.The budget impact was investigated by comparing the difference in the total cost of two scenarios:Trilaciclib was included and Trilaciclib was not included by the national insurance.RESULTS:From 2025 to 2029,compared with the scenario without trilaciclib application,in the scenario with trilaciclib application,the cost of prophylactic long-acting granulocyte colony-stimulating factor(G-CSF)was saved by 313 565 317 yuan;the treatment cost of myelosuppression events was saved by 1 134 629 776 yuan;the total treatment cost of trilaciclib during this period was 1 090 365 714 yuan.After the use of trilaciclib,it was predicted that a total of 123 776 124 yuan in medical insurance budget would be saved from 2025 to 2029,and the average monthly treatment cost per patient would be reduced by 4.36 yuan.CONCLUSIONS:Trilaciclib can reduce the costs related to prophylactic medication and the management of myelosuppression events,and can effectively lower the total expenditure of the national health insurance fund.